

Euro Ewing 2012 – Information for patients and carers

The aim of the Euro Ewing 2012 trial is to compare different chemotherapy regimens to determine which is more effective and/or has fewer side effects.

Why is this trial being run?

The trial is comparing two treatments, known as treatment arms A and B.

Treatment arm A is the chemotherapy that is the standard treatment used in Europe whereas treatment arm B is the chemotherapy that is used in the USA. The trial is being run as we do not know which treatment is best.

A second reason for running the trial is to test if a drug called zoledronic acid can improve treatment for Ewing sarcoma. Zoledronic acid has been widely used for the treatment of other bone diseases and cancers that start in or spread to the bone, so we think that it may offer benefit for patients with Ewing sarcoma without worsening the side effects of the chemotherapy. We do not know whether this is the best treatment for patients with Ewing sarcoma.

Can I take part in the trial?

If you have been recently diagnosed with Ewing sarcoma for the first time, you may be able to take part in the trial. Your doctor will explain whether you are able to take part. Your doctor will review your diagnostic tests and medical notes to see if you are eligible to take part in the trial.

What treatment will I receive?

Treatment arm A

In the first part of the trial, if you are given treatment arm A you will receive a type of chemotherapy called VIDE, followed by surgery and/or radiotherapy, then more chemotherapy.

After surgery and/ or radiotherapy, you will have the opportunity to take part in the second part of the trial which tests zoledronic acid.

The doctors will see how well you have responded to the treatment so far and then decide which treatment would be best for you. You will receive either VAC or VAI chemotherapy. At the same time as receiving VAC or VAI, half of the patients will receive zoledronic acid. You may be in the group that receives zoledronic acid.

Treatment arm B

If you are given treatment arm B you will receive a type of chemotherapy called VDC/IE, followed by surgery and/or radiotherapy, then more chemotherapy.

After surgery and/ or radiotherapy, you will have the opportunity to take part in the second part of the trial.

You will receive IE/VC chemotherapy. At the same time as receiving IE/VC, half of the patients will receive zoledronic acid. You may be in the group that receives zoledronic acid.

For more detailed information, please go to the following websites:

Country	Website
UK	http://www.cancerresearchuk.org/about-cancer/trials/a-trial-

	looking-treatment-ewings-sarcoma-family-of-tumours-euro-ewing-2012
Spain	https://reec.aemps.es/reec/faces/buscador/index.xhtml

Can I choose which treatment arm I receive?

No. Euro Ewing 2012 is a randomised trial so you will be randomly assigned to a treatment arm by a computer. This is done so that neither you or your doctor will be able to influence which treatment arm you receive and means that the results of the trial are not biased in any way.

Where is the trial running?

At present (July 2015), the trial is recruiting patients at hospitals in the following locations and will open in other countries outside of the UK, Spain and France over the next months:

UK	
Aberdeen	Royal Aberdeen Children's Hospital
Belfast	Royal Belfast Hospital for Sick Children
Birmingham	Birmingham Children's Hospital Queen Elizabeth Hospital, Birmingham
Bristol	Bristol Royal Hospital for Children Bristol Haematology and Oncology
Cambridge	Addenbrooke's Hospital
Cardiff	Children's Hospital for Wales, Cardiff
Edinburgh	Royal Hospital for Sick Children, Edinburgh
Glasgow	Royal Hospital for Sick Children, Glasgow
Leeds	Leeds General Infirmary
Leeds	St James's University Hospital
Leicester	Leicester General Infirmary
Liverpool	Alder Hey Children's Hospital, Liverpool
London	Great Ormond Street Hospital University College London Hospital
Manchester	Royal Manchester Children's Hospital The Christie Hospital, Manchester
Newcastle	Royal Victoria Infirmary, Newcastle
Nottingham	Queen's Medical Centre, Nottingham Nottingham City Hospital
Oxford	John Radcliffe Hospital, Oxford
Sheffield	Sheffield Children's Hospital Weston Park Hospital, Sheffield
Southampton	Southampton General Hospital
Sutton	Royal Marsden Hospital Sutton (paediatrics)

Spain	
Barakaldo	Hospital De Cruces
Barcelona	Hospital De La Sant Creu I Sant Paul
Barcelona	Ico Hospitalet
Barcelona	Hospital Universitari Vall D'hebron
Madrid	Grupo Espanol De Investigacion En Sarcomas
Madrid	Hospital Del Nino Jesus
Madrid	Hospital La Paz
Madrid	Hospital Puerta De Hierro
Madrid	Hospital Universitario Gregorio Maranon
Malaga	Hospital Clinico Virgen De La Victoria
Malaga	Hospital Regional Universitario de Málaga
Oviedo	Hospital Central De Asturias
Palma De Mallorca	Hospital Son Espases
Seville	Hospital Virgen del Rocío
Tenerife	Hospital Canarias
Valencia	Hospital Politecnico U La Fe
Zaragoza	Hospital Miguel Servet

France	
Lyon	Centre Leon Berard

How many patients will take part?

600 patients will be recruited from across Europe between 2013 and 2018.

How can I find out more information?

- Read more at Cancer Research UK
- Discuss it with your doctor who will be able to find out more information for you

How can I take part in the trial?

Talk about the trial with your doctor who will find out if you are eligible and if so, help you to take part.